Background: Recently, new evidence from large scale trials and updated guidelines
Introduction
Worldwide clinical registry data of 114 364 MI survivors from Sweden, US, UK and France 1 have shown that, in the real-world, acute coronary syndrome (ACS) patients remain at risk long after initial diagnosis. The 3-year incidence of myocardial infarction (MI), stroke or death, in MI patients who have been event-free for 1 year was approximately one in five; for patients aged >65, it increased to approximately one in four. New evidence has emerged on the risks and benefits of antiplatelet therapy, including extended dual antiplatelet therapy (DAPT), for patients with ACS, such as from the largescale DAPT and PEGASUS trials. The DAPT study 2 tested thienopyridine + aspirin versus aspirin alone in 9961 patients, for beyond 12 months and up to 30 months after drug-eluting stenting. The results showed a 29% significant reduction in major adverse cardiovascular and cerebrovascular events (MACCE) in the extended DAPT group compared with the placebo group (4.3% vs 5.9%, HR = 0.71 (95% CI: 0.59-0.85), P < 0.001). The PEGASUS study 3 recruited 21 162 stable patients with a history of MI in the past 1-3 years, with ≥1 additional atherothrombotic risk factor, including age >65 years, diabetes, second prior MI, multi-vessel coronary artery disease (CAD) or chronic non-end-stage renal dysfunction with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m 2 . The extended DAPT arm with ticagrelor demonstrated a 15-16% reduction vs the placebo arm: (i) with 90 mg twice daily ticagrelor vs placebo, HR = 0.85 (95% CI: 0.75-0.96, P = 0.008) and (ii) with 60 mg twice daily ticagrelor vs placebo, HR = 0.84 (95% CI: 0.74-0.95, P < 0.001).
The European Society of Cardiology (ESC) has issued 2017 guideline updates with relevance to antiplatelet therapy in ACS patients. 4, 5 In the STEMI guideline update, 4 for high ischaemic-risk patients who tolerated DAPT without a bleeding complication, DAPT is recommended in the form of aspirin + ticagrelor 60 mg twice daily for >12 months and up to 3 years. The DAPT guideline update 5 recommends that when an ACS patient is exposed to clopidogrel, and ticagrelor is available, an early switch to ticagrelor after hospital admission is recommended. In terms of withdrawal time for elective non-cardiac surgery, the guideline now recommends 7 days for prasugrel, 5 days for clopidogrel and 3 days for ticagrelor. 5 Details are still lacking on individual patient selection based on balancing risk factors, and particularly regarding the characteristics of Asian populations. This paper resulted from a series of expert meetings, with an objective to discuss, clarify and advise on the application of the new evidences and guidelines concerning extended DAPT for ACS patients to clinical practice.
Methods
A total of 14 local cardiologists with extensive experience in cardiology and cardiac interventions convened in a series of three advisory board meetings that were held on 27 October 2016, 14 December 2016 and 22 September 2017 in Hong Kong. The objective was to discuss the application of recently updated international guidelines and research evidences on antiplatelet therapy for ACS patients to clinical practice, with a focus on the significance of individual risk factors in Asian patients, in terms of their likelihood to cause ischaemia or bleeding. In each meeting, (i) the chairperson provided a review of major literature evidences, some of which were included in the present Introduction; (ii) latest clinical trends concerning various risk factors were discussed; (iii) an anonymous, electronic voting system was used to indicate agreement or disagreement, and to indicate ratings on risk factors.
The first meeting described the existing practices of antiplatelet therapy for ACS patients, the second meeting elaborated on various ischaemic and bleeding risk factors for consideration and the third meeting focused on several selected major risk factors. Consensuses were reached when ≥80% of attendants demonstrated agreement (falling on the top two choices of a rating scale, or on a single categorical answer). When ≥80% of the panellists' votes fell on the upper (or lower) two choices of the rating scale, the risk factor was classified as a strong ischaemic (or bleeding) risk. Otherwise, the risk factor was classified as an ischaemic or bleeding risk based on the discussions and averaging of the voting results.
The design and conduction of the study followed the principles of the Helsinki Declaration for studies involving human subjects. No institutional ethics approval was required.
Results
The panellists agreed to select ACS patients for antiplatelet therapy based on balancing between ischaemic and bleeding risks. The final consensuses of the panellists (in the last of the three meetings) are illustrated in Table 1 . Hence, for patients with one or more of the five 'classic' ischaemic risk factors: old age (>65), chronic kidney disease (CKD), diabetes mellitus (DM), recurrent MI and/or multi-vessel disease (MVD), extended DAPT beyond 12 months may be considered, while balancing the bleeding risk of old age and/or CKD if present. The panellists noted that patients with CKD tend to have problems besides high cholesterol, including hypertension, hyperphosphatemia and endothelial damage; thus, reducing cholesterol alone might be insufficient to improve disease condition. Moreover, modifying lipids, such as through increasing HDL cholesterol level and cholesterol efflux capacity, 10 may take longer time to work than antiplatelet action.
Regarding stenting, three aspects should be considered: location, amount of metals and stent type, in relation to two types of events: progressive in-stent restenosis and stent thrombosis. Stent thrombosis tends to happen more immediately than in-stent restenosis, but improvements in stent designs have delayed the former's occurrence, and extended DAPT may also be helpful. For heavily calcified stents that are not well-expanded, extended DAPT would be a major option. The panellists observed clinically that bioresorbable vascular scaffold (BVS) stents have been associated with increased thrombotic risks. 8 In terms of left main disease (with stenting), although solid data are lacking, extended DAPT can be considered because the extent of myocardial damage can be grave in case of an event happening at the location.
In terms of the choices of prescriptions, the panellists remarked that physicians in Hong Kong have developed a habit of prescribing aspirin + clopidogrel to ACS patients. Further considerations would include: nonresponse to clopidogrel in certain patients, 11 the higher required loading dose for clopidogrel, 5 the quicker onset of ticagrelor, 12 and the more days required for stopping clopidogrel than ticagrelor. 5 (See 13 for a meta-analysis on the efficacy and safety of P2Y12 inhibitors.) It was noted that for extended DAPT, ticagrelor 60 mg BID demonstrated comparable efficacy to 90 mg BID, 3 while the lowered dose should in theory lead to a lessened bleeding risk. For patients and physicians who are concerned about bleeding, ticagrelor may now be prescribed more often at 60 mg BID over clopidogrel.
Discussion
The strengths of the present recommendations include: (i) affirming a single, clear principle of balancing between ischaemic and bleeding risks for patient selection; (ii) providing concise descriptions of the rationale for identifying each risk factor as an ischaemic or bleeding risk factor, with simple ratings (Table 1 ). The recommendations were the results of the extensive experience of the panellists in treating Asian patients, and of their in-depth understanding of the latest clinical trends and research evidences. Limitations include having surveyed the most recent literature, but not opting to perform a systematic review. However, our main question of how to select ACS patients for antiplatelet therapy is based on a spectrum of risk factors, and it seems that a systematic review cannot cover all the risk factors considered. While a systematic review would lend further support, an expert panel discussion would be effective for addressing such a question. Noting that all the experts, although having long-term public service experiences, were in private practice at the time of the meetings, there might have been a bias toward favouring less affordable treatments. Nonetheless, private practitioners in Hong Kong are arguably more experienced in using medications that are not on the main formulary of public care, including some of the antiplatelet drugs discussed here, which would have enriched the discussions.
Conclusion
ACS patients with ischaemic risk factors could be considered for extended DAPT beyond 12 months, while balancing the risk of bleeding. Strong ischaemic risk factors include DM, recurrent MI, MVD and/or >3 stents; lessstrong ischaemic factors include CKD, left main stenting, BVS stents and peripheral artery disease. Old age can be an unclear risk factor due to variations in body build among patients. 
